PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Both companies show declining cash positions (-9.09% vs AGEN's -25.77%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Below half of AGEN's -32.66%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Above 1.5x AGEN's -18.08%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-10.41%
Below half of AGEN's -26.46%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-5.27%
≥ 1.5x AGEN's -2.41%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Below half of AGEN's 37.47%. Michael Burry sees possible underinvestment in long-term assets. Verify capital constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
≥ 1.5x AGEN's -1.38%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
0.75-0.9x AGEN's -12.54%. Bill Ackman questions if competitor invests more aggressively for growth.
-5.64%
Less than half of AGEN's -22.11%. David Dodd sees a more disciplined AP approach or lower volume.
1.56%
Less than half of AGEN's -37.78%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Less than half of AGEN's 0.75%. David Dodd sees fewer expansions in other current obligations.
-5.23%
Above 1.5x AGEN's -2.80%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Less than half of AGEN's -1.51%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
50-75% of AGEN's -2.08%. Bruce Berkowitz notes a lower yoy liability increase.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
1.25-1.5x AGEN's -3.37%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
Below half AGEN's -38.54%. Michael Burry sees potential underperformance in building shareholder capital.
-10.20%
0.75-0.9x AGEN's -12.54%. Bill Ackman wonders if competitor invests or leverages more aggressively.
0.98%
Below half AGEN's -74.95%. Michael Burry suspects major underinvestment or forced divestment.
-5.39%
Less than half of AGEN's 1.92%. David Dodd sees less overall debt expansion vs. competitor.
9.19%
Less than half of AGEN's 69.06%. David Dodd sees better deleveraging or stronger cash buildup than competitor.